Diabetes, obesity & metabolismHumansBenzhydryl CompoundsDiabetes MellitusType 2Glucosides
Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.
Phyo Than Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J Wexler, Robert J Glynn, Elyse DiCesare, Ariel Freedman, Niklas Schmedt, Christina Shay, Julie M Paik, Elisabetta Patorno
Published: 202610.1111/dom.70195
Abstract
AIMS: Understanding the real-world impact of treatment with empagliflozin and glucagon-like peptide-1 receptor agonists (GLP-1RA) on healthcare resource utilization (HCRU) and costs could help inform clinical decision-making and healthcare policy. MA…
Preview only. Read the full abstract at the source